A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.

Inclusion Criteria:

• Histologic or cytologic diagnosis of pancreatic adenocarcinoma (locally advanced disease that is not surgically resectable, or distant metastatic disease)
• Participants must have measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) guidelines
• Participants must not have received prior chemotherapy, immunotherapy or chemoradiotherapy for advanced pancreas cancer
• Karnofsky performance status (KPS) of 70-100
• Adequate hematologic, hepatic and renal function